Guidelines for anti-emetic therapy: Acute emesis

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 361-370

  Fauser, A A ^a   Fellhauer, M ^b   Hoffmann, M ^c   Link, H ^d   Schlimok, G ^e   Gralla, R J ^f  

^a BMT Hospital   (Germany)

^b 78011   (Germany)

^c Bremserstr 79 67063 Ludwigshafen   (Germany)

^d 67653   (Germany)

^e KLINIKUM AUGSBURG   (Germany)

^f Ochsner Cancer Institute   (United States)

Author keywords

5 hydroxytryptamine (5 HT3) antagonist; Anti emetic therapy; Cancer; Chemotherapy; Corticosteroid; Emesis; Serotonin antagonist; Supportive care

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DOLASETRON MESILATE; ETOPOSIDE; GEMCITABINE; GRANISETRON; IDARUBICIN; IRINOTECAN; MELPHALAN; METHYLPREDNISOLONE; METOCLOPRAMIDE; MITOMYCIN; MITOXANTRONE; NAVELBINE; ONDANSETRON; PACLITAXEL; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TENIPOSIDE; TOPOTECAN; TROPISETRON; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER PATIENT; DOSE CALCULATION; DRUG CHOICE; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VOMITING;

EID: 0033105567     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00417-1     Document Type: Article

References (94)

1. Nolte M.J., Berkery R., Pizzo B., et al. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 16:1998;771-778.
2. American Society of Clinical Oncology. Recommended breast cancer surveillance guidelines. J Clin Oncol 1997, 15, 2149-2156.
3. Audhuy B., Cappelaere P., Martin M., et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur J Cancer. 32A:1996;807-813.
4. Fauser A.A., Duclos B., Chemaissani A., et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer. 32A:1996;1523-1529.
5. Navari R., Gandara D., Hesketh P., et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol. 13:1995;1242-1248.
6. Coates A., Abraham S., Kaye S.B., et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 19:1983;203-208.
7. Cooper S., Georgiou V. The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer. 28A:(Suppl. 1):1992;S36-S38.
8. Chevallier B., Cappelaere P., Splinter T., et al. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer. 5:1997;22-30.
9. Perez E.A., Lembersky B., Kaywin P., et al. Intravenous (IV) granisetron vs ondansetron in the prevention of cyclophosphamide-doxorubicin-induced emesis in breast cancer patients: a double-blind crossover study (abstract). Proc Am Soc Clin Oncol. 15:1996;543.
10. Perez E.A., Hesketh P., Sandbach J., et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 16:1998;754-760.
11. Ruff P., Paska W., Goedhals L., et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology. 51:1994;113-118.
12. Bonneterre J, Hecquet B on behalf of the French Northern Oncology Group. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy: a cross-over study. Bull Cancer 1995, 82, 1038-1043.
13. Markham A., Sorkin E.M. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs. 45:1993;931-952.
14. Plosker G.L., Goa K.L. Granisetron: a review of its pharmacological properties and therapeutic use as an antiemetic. Drugs. 42:1991;805-824.
15. Gralla R.J. Anti-emesis with cancer chemotherapy. Eur J Cancer. 33:(Suppl. 4):1997;S63-S67.
16. 3 receptor antagonists. Support Care Cancer. 2:1994;286-292.
17. 3 receptor antagonist. Drug Dev Res. 34:1995;289-296.
18. 3 receptors. Br J Pharmacol. 94:1988;397-412.
19. Richardson B.P., Engel G., Donatsch P., et al. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature. 316:1985;126-131.
20. 3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol. 159:1989;113-124.
21. Balfour J.A., Goa K.L. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 54:1997;273-298.
22. Lee C.R., Plosker G.L., McTavish D. Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs. 46:1993;925-943.
23. Hesketh P., Navari R., Grote T., et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol. 14:1996;2242-2249.
24. Marty M., Kleisbauer J-P., Fournel P., et al. Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs. 6:(Suppl. 1):1995;15-21.
25. Stewart A., McQuade B., Cronje J.D.E., et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology. 52:1995;202-210.
26. Adams M., Soukop M., Barley V., et al. Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. Anti-Cancer Drugs. 6:1995;514-521.
27. Schmidt M., Sorbe B., Hogberg T., et al. Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin. Ann Oncol. 4:(Suppl. 3):1993;S31.
28. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol. 17:1994;97-102.
29. Grote T.H., Pineda L.F., Figlin R.A., et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am. 3:1997;45-51.
30. Harman G.S., Omura G.A., Ryan K., et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol. 38:1996;323-328.
31. Kris M.G., Grunberg S.M., Gralla R.J., et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol. 12:1994;1045-1049.
32. Rubenstein E.B., Gralla R.J., Hainsworth J.D., et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer. 79:1997;1216-1224.
33. Thant M., Pendergrass K., Harman G., et al. Double-blind randomized study of the dose-response relationship across five single doses of IV dolasetron mesylate (DM) for prevention of acute nausea and vomiting (ANC) after cisplatin chemotherapy (CCT) (abstract). Proc Am Soc Clin Oncol. 15:1996;533.
34. Yeilding A., Bertoli L., Eisenberg P., et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol. 19:1996;619-623.
35. Ettinger D.S., Eisenberg P.D., Fitts D., et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer. 78:1996;144-151.
36. Navari R.M., Kaplan H.G., Gralla R.J., et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 12:1994;2204-2210.
37. Riviere A, on behalf of The Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994, 69, 967-971.
38. Smith IE, on behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 1990, 26(Suppl 1), S19-S23.
39. Beck T.M., Ciociola A.A., Jones S.E., et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med. 118:1993;407-413.
40. Brown G.W., Paes D., Bryson J., et al. The effectiveness of a single intravenous dose of ondansetron. Oncology. 49:1992;273-278.
41. Fraschini G., Ciociola A., Esparza L., et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 9:1991;1268-1274.
42. Grunberg S.M., Lane M., Lester E.P., et al. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol. 32:1993;268-272.
43. Rosso R., Carnpora E., Cetto G., et al. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide induced emesis. Anticancer Res. 11:1991;937-940.
44. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992, 10, 1969-1975.
45. Hainsworth J.D., Hesketh P.J. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin Oncol. 19:(6 Suppl. 15):1992;14-19.
46. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. J Cancer Res Clin Oncol. 123:1997;224-226.
47. Pectasides D., Mylonakis A., Varthalitis J., et al. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis. Oncology. 54:1997;1-6.
48. Gebbia V., Cannata G., Testa A., et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer. 74:1994;1945-1952.
49. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer. 29A:1993;1669-1672.
50. Mantovani G., Macciò A., Bianchi A., et al. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer. 77:1996;941-948.
51. Gralla R.J., Popovic W., Strupp J., et al. Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: results of a 1054 patient randomized study of oral granisetron versus IV ondansetron (abstract). Proc Am Soc Clin Oncol. 16:1997;52a.
52. Perez E.A. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Ther. 18:1996;578-590.
53. Farthing M.J.G. 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scand J Gastroenterol. 26:(Suppl 188):1991;92-100.
54. Andrews P.L.R., Davis C.J., Bingham S., et al. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 68:1990;325-345.
55. Beck T.M., York M., Chang A., et al. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Invest. 15:1997;297-303.
56. Chua D.T., Sham J.S., Au G.K., et al. The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial. Br J Clin Pharmacol. 41:1996;403-408.
57. Crucitt M.A., Hyman W., Grote T., et al. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin Ther. 18:1996;778-788.
58. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995, 332, 1-5.
59. Roila F., Tonato M., Cognetti F., et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 9:1991;674-678.
60. Gralla R.J. Current issues in the management of nausea and vomiting. Ann Oncol. 4:(Suppl 3):1993;S3.
61. Aapro M.S., Plezia P.M., Alberts D.S., et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol. 2:1984;466-471.
62. Kris M.G., Gralla R.J., Tyson L.B., et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine: results of consecutive trials in 255 patients. Cancer. 55:1985;527-534.
63. Roila F., Tonato M., Basurto C., et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metaclopramide combined with methylprednisolone versus metoclopramide with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol. 7:1989;1693-1700.
64. Parry H., Martin K. Single-dose i.v. dexamethasone - an effective anti-emetic in cancer chemotherapy. Cancer Chemother Pharmacol. 28:1991;231-232.
65. Lofters W.S., Zee B. Dolasetron (dol) versus ondansetron (ond) with and without dexamethasone (dex) in the prevention of nausea (N) and vomiting (V) in patients receiving moderately emetogenic chemotherapy (MEC). Eur J Cancer. 31A:(Suppl 5):1995;S252.
66. Kris M.G., Pendergrass K.B., Navari R.M., et al. Prevention of acute emesis following high-dose cisplatin with the combination of oral dolasetron and dexamethasone [abstract no. 105]. Support Care Cancer. 4:(3):1996;250.
67. Fozard J.R., Mobarok Ali A.T. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol. 49:1978;109-112.
68. DeMulder P.H.M., Seynaeve C., Vermorker J.B., et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med. 113:1990;834-840.
69. Hesketh P.J. Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. Semin Oncol. 19:(4 Suppl. 10):1992;33-40.
70. Sledge Jr G.W., Einhorn L., Nagy C., House K. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 70:1992;2524-2528.
71. Soukop M., McQuade B., Hunter E., et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 49:1992;295-304.
72. Bowcock S.J., Stockdale A.D., Bolton J.A.R., Kang A.A., Retsas S. Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. Br Med J. 288:1984;1879.
73. Kris M.G., Gralla R.J., Clark R.A., et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep. 69:1985;1257-1262.
74. Kris M.G., Gralla R.J., Clark R.A., et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer. 69:1987;1353-1357.
75. Dilly S.G., Friedman C., Yocum K. Contribution of dexamethasone to antiemetic control with granisetron is greatest in patients at high risk of emesis (abstract). Proc Am Soc Clin Oncol. 13:1994;436.
76. Kris M.G., Pendergrass K.B., Navari R.M., et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 15:1997;2135-2138.
77. Lofters W.S., Pater J.L., Zee B., et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 15:1997;2966-2973.
78. Peterson C., Hursti T.J., Börjeson S., et al. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer. 4:1996;440-446.
79. Sekine I., Nishiwaki Y., Kakinuma R., et al. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis. Jpn J Clin Oncol. 26:1996;164-168.
80. Silva R.R., Basconi R., Giorgi F., et al. Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Support Care Cancer. 4:1996;287-290.
81. Bruera E.D., Roca E., Cedaro L., Chacon R., Estevez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep. 67:1983;381-383.
82. Grunberg S.M., Akerley W.L., Krailo M.D., Johnson K.B., Baker C.R., Cariffe P.A. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest. 4:1986;379-385.
83. Shinkai T., Saijo N., Eguchi K., et al. Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol. 16:1986;279-287.
84. Strum S.B., McDermed J.E., Liponi D.F. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. J Clin Oncol. 3:1985;245-251.
85. Korttila, K., Maillet, M., Diemunsch, P., et al. IV dolasetron mesylate (DM) vs iv ondansetron (OND) for prevention of post operative nausea and vomiting (PONV) (abstract no. A36). Anesthesiology 1996, 85(3A).
86. Chin S.B.Y., Kucuk O., Peterson R., Ezdinli E.Z. Variables contributing to anticipatory nausea and vomiting in cancer chemotherapy. Am J Clin Oncol. 15:1992;262-267.
87. Hesketh PJ, Plagge P, Bryson JC. Single-dose ondansetron for the prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In Bianchi AL, Grélot L, Miller AD, King GL, eds. Mechanisms and Control of Emesis. London, John Libbey Eurotext, 1992, 235-236.
88. D'Acquisto R., Tyson L.B., Gralla R.J., et al. The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting (abstract). Proc Am Soc Clin Oncol. 5:1986;257.
89. Sullivan J.R., Leyden M.J., Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion (letter). N Engl J Med. 309:1983;796.
90. Tonato M., Roila F., Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol. 2:1991;107-114.
91. Mystakidou K., Befon S., Liossi C., et al. Comparison of the efficacy and safety of tropisetron, metoclopramide and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 83:(6):1998;1214-1223.
92. Hesketh P.J., Kris M.G., Grunberg S.M., et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 15:1997;103-109.
93. Homesley H.D., Gainey J.M., Jobson V.N., et al. Cisplatin chemotherapy and emesis in patients given metoclopramide and controls. N Engl J Med. 307:1982;250-251.
94. du Bois A., McKenna C.J., Andersson H., et al. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Oncology. 54:1997;7-14.